<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Neurol.</journal-id>
<journal-title>Frontiers in Neurology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Neurol.</abbrev-journal-title>
<issn pub-type="epub">1664-2295</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fneur.2021.780436</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Neurology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Extracranial Carotid Plaque Hemorrhage Is Independently Associated With Poor 3-month Functional Outcome After Acute Ischemic Stroke&#x02014;A Prospective Cohort Study</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Che</surname> <given-names>Fengli</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1395196/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Liu</surname> <given-names>Yanfang</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1095197/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Gong</surname> <given-names>Xiping</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1128646/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Wang</surname> <given-names>Anxin</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1437257/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Bai</surname> <given-names>Xiaoyan</given-names></name>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1035727/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Ju</surname> <given-names>Yi</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/965894/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Sui</surname> <given-names>Binbin</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1131780/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Jing</surname> <given-names>Jing</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1276911/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Geng</surname> <given-names>Xiaokun</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff5"><sup>5</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/629086/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Zhao</surname> <given-names>Xingquan</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<xref ref-type="aff" rid="aff6"><sup>6</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x0002A;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/898521/overview"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Department of Neurology, Beijing Tiantan Hospital, Capital Medical University</institution>, <addr-line>Beijing</addr-line>, <country>China</country></aff>
<aff id="aff2"><sup>2</sup><institution>Department of Neurology, Beijing Luhe Hospital, Capital Medical University</institution>, <addr-line>Beijing</addr-line>, <country>China</country></aff>
<aff id="aff3"><sup>3</sup><institution>Tiantan Neuroimaging Center for Excellence, Beijing Tiantan Hospital, Capital Medical University</institution>, <addr-line>Beijing</addr-line>, <country>China</country></aff>
<aff id="aff4"><sup>4</sup><institution>Department of Neuroradiology, Beijing Tiantan Hospital, Capital Medical University</institution>, <addr-line>Beijing</addr-line>, <country>China</country></aff>
<aff id="aff5"><sup>5</sup><institution>Department of Neurology, China-America Institute of Neuroscience</institution>, <addr-line>Beijing</addr-line>, <country>China</country></aff>
<aff id="aff6"><sup>6</sup><institution>Research Unit of Artificial Intelligence in Cerebrovascular Disease, Chinese Academy of Medical Sciences</institution>, <addr-line>Beijing</addr-line>, <country>China</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited by: Edgar A. Samaniego, The University of Iowa, United States</p></fn>
<fn fn-type="edited-by"><p>Reviewed by: Marialuisa Zedde, Local Health Authority of Reggio Emilia, Italy; Danhong Wu, Fudan University, China</p></fn>
<corresp id="c001">&#x0002A;Correspondence: Xingquan Zhao <email>zxq&#x00040;vip.163.com</email></corresp>
<fn fn-type="other" id="fn001"><p>This article was submitted to Stroke, a section of the journal Frontiers in Neurology</p></fn></author-notes>
<pub-date pub-type="epub">
<day>14</day>
<month>12</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="collection">
<year>2021</year>
</pub-date>
<volume>12</volume>
<elocation-id>780436</elocation-id>
<history>
<date date-type="received">
<day>21</day>
<month>09</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>15</day>
<month>11</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2021 Che, Liu, Gong, Wang, Bai, Ju, Sui, Jing, Geng and Zhao.</copyright-statement>
<copyright-year>2021</copyright-year>
<copyright-holder>Che, Liu, Gong, Wang, Bai, Ju, Sui, Jing, Geng and Zhao</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license> </permissions>
<abstract><p><bold>Background and Purpose:</bold> Carotid plaque hemorrhage (IPH) is a critical plaque vulnerable feature. We aim to elucidate the association between symptomatic extracranial carotid atherosclerotic IPH and poor 3-month functional outcome after acute ischemic stroke by high-resolution vessel wall MRI (HRVMRI).</p>
<p><bold>Methods:</bold> We prospectively studied consecutive patients with a recent stroke or transient ischemic attack (TIA) of carotid atherosclerotic origin. All patients underwent a High-Resolution (HR) VWMRI scan of ipsilateral extracranial carotid within 1 week after admission. The patients recruited were interviewed by telephone after 3 months after stroke onset. The primary outcome was a 3-month functional prognosis of stroke, expressed as a modified Rankin Scale (mRS) score. A poor prognosis was defined as a 3-month modified Rankin Scale (mRS) score &#x02265; of 3. Univariate analysis was used to analyze the correlation between risk factors and IPH. The relation between IPH and 3-month functional outcome was analyzed by Logistic regression analysis.</p>
<p><bold>Results:</bold> A total of 156 patients (mean age, 61.18 &#x000B1; 10.12 years; 108 males) were included in the final analysis. There were significant differences in the age, gender, smoking history, national institutes of health stroke scale (NIHSS) on admission, and diastolic blood pressure (DBP) on admission between the IPH group and the non-IPH group (all <italic>p</italic> &#x0003C; 0.05). During the follow-up, 32 patients (20.5%) had a poor functional outcome. According to the prognosis analysis of poor functional recovery, there was a significant difference between the two groups [36.7 vs. 16.7%; unadjusted odds ratio (OR), 2.32, 95% confidence interval (CI), 1.12&#x02013;4.81, <italic>p</italic> = 0.024). Even after adjusting for confounding factors [such as age, gender, smoking history, National Institutes of Health Stroke Scale (NIHSS) on admission, DBP on admission, stenosis rate of carotid artery (CA), calcification, loose matrix, lipo-rich necrotic core (LRNC), and statins accepted at 3 months], IPH was still a strong predictor of poor 3-month outcome, and the adjusted OR was 3.66 (95% CI 1.68&#x02013;7.94, <italic>p</italic> = 0.001).</p>
<p><bold>Conclusions:</bold> Extracranial carotid IPH is significantly associated with poor 3-month outcome after acute ischemic stroke and can predict the poor 3-month functional prognosis.</p></abstract>
<kwd-group>
<kwd>MRI</kwd>
<kwd>atherosclerosis</kwd>
<kwd>plaque</kwd>
<kwd>prognosis</kwd>
<kwd>acute ischemic stroke</kwd>
</kwd-group>
<contract-sponsor id="cn001">Beijing Municipal Natural Science Foundation<named-content content-type="fundref-id">10.13039/501100005089</named-content></contract-sponsor>
<counts>
<fig-count count="3"/>
<table-count count="2"/>
<equation-count count="0"/>
<ref-count count="20"/>
<page-count count="8"/>
<word-count count="4550"/>
</counts>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="s1">
<title>Introduction</title>
<p>Atherosclerosis is the leading cause of ischemic stroke in the Chinese population (<xref ref-type="bibr" rid="B1">1</xref>). The Chinese Intracranial Atherosclerosis Study (CICAS) showed that 14% of patients with ischemic stroke had severe extracranial carotid atherosclerosis (&#x0003E; of 50%). Some studies have confirmed that carotid artery atherosclerotic stenosis is significantly associated with the onset and prognosis of acute ischemic stroke (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B3">3</xref>). However, histopathological studies have demonstrated that the vulnerable features of carotid artery plaque are the underlying risk factors of most ischemic events (<xref ref-type="bibr" rid="B4">4</xref>&#x02013;<xref ref-type="bibr" rid="B10">10</xref>). Therefore, identifying the vulnerable plaques based on advanced medical imaging technology and exploring the correlation between the vulnerability of the plaque and stroke recurrence has become research hotspots in recent years. Meanwhile, we still do not know whether the characteristics of carotid artery plaques in acute ischemic stroke are associated with the poor 3-month outcome of patients after stroke onset.</p>
<p>Our study aims to analyze the vulnerable characteristics of carotid plaque by high-resolution vessel wall magnetic resonance imaging (HR VWMRI) and find a relation between IPH and the early poor prognosis of acute ischemic stroke. With that in mind, we might identify the risk factors of poor 3-month outcome of stroke and take more effective individualized prevention strategies in the acute stage of ischemic stroke.</p>
</sec>
<sec sec-type="methods" id="s2">
<title>Methods</title>
<sec>
<title>Study Population</title>
<p>All patients were enrolled from a single-center prospective cohort study in Beijing Tiantan Hospital. We aimed to assess the characteristics of carotid atherosclerotic plaques and the relationship between IPH and poor 3-month outcome after stroke onset. All enrolled patients underwent an ultrasonographic screen and a HR VWMRI scan of the symptomatic extracranial carotid artery within 1 week after admission. They were followed up by telephone after 3 months (90 &#x000B1; 7 days) after stroke onset. According to the latest international guidelines, we gave the enrolled patients standardized medical therapy and secondary prevention of stroke. In addition, the inclusion criteria and exclusion criteria of the study have been mentioned in the <xref ref-type="supplementary-material" rid="SM1">Supplementary Material</xref>. The Ethics Committee approved the study of Beijing Tiantan Hospital. All study subjects had signed written consent.</p>
</sec>
<sec>
<title>Carotid MR Imaging Protocol</title>
<p>All recruited subjects were scanned using 3.0 T MR scanners (Achieva TX; Philips Healthcare, Best, the Netherlands) with 8-channel head coils. A standardized multisequence protocol included three-dimensional time of flight (3D-TOF), T1-weighted quadruple inversion recovery, T2-weighted multislice double, and magnetization prepared gradient recalled echo (MPRAGE) imaging sequences. We used gadolinium diethylenetriamine pentametric acid (GD-DTPA) as the contrast medium, and the injection dose was 0.1 mmol/kg. We used spectral preservation attenuated inversion recovery (SPAIR) in the black blood technique. The study&#x00027;s imaging parameters of carotid atherosclerotic plaque MRI have also been mentioned in the <xref ref-type="supplementary-material" rid="SM1">Supplementary Material</xref>.</p>
</sec>
<sec>
<title>MRI Image Analysis</title>
<p>We used a standard workstation (ADW4.4, G.E. Medical System, USA) for imaging analysis. Two experienced senior neuroimaging physicians reviewed all slices of multi-contrast MR vessel wall images. They were both blinded to the diffusion-weighted images (DWI) and clinical information. The plaque was defined as a thickening of the focal wall relative to image slices beneath the T2 and T1-weighted imaging focal wall. We manually outlined the outer wall boundaries and lumen of carotid arteries at each slice. The parameters of plaque morphology and the stenosis ratio of the carotid were measured. According to the international criteria detailed previously, the plaque components such as carotid artery (CA), lipo-rich necrotic core (LRNC), IPH, and fibrous cap rupture (FCR) were detected by MRI (<xref ref-type="bibr" rid="B11">11</xref>). MR image quality was divided into a four-point grade (1 = poor; 2 = general; 3 = good; and 4 = excellent), and slices with image quality &#x02265; 3 were included in the statistical analysis. We would accept consensus interpretation as the final analysis if inconsistent in the two readers&#x00027; interpretations. We randomly selected twenty patients from the study population every 2 months to test the consistency of inter-reader and intra-reader in measuring carotid plaque morphology and carotid plaque compositions.</p>
</sec>
<sec>
<title>Outcome Assessment</title>
<p>Patients were followed up at 3 months after stroke onset. The primary outcome was 3-month functional outcome, expressed as a modified Rankin Scale (mRS) score 3 months after discharge. A poor functional outcome was defined as mRS score &#x02265;of 3 at 3 months. The secondary outcomes were early stroke progression, early recurrent ischemic stroke, and hemorrhagic transformation at 3 months post-discharge. The recurrence of ischemic stroke was confirmed according to new neurological deficits documented in the medical records. Two experienced stroke neurologists reviewed patients&#x00027; medical documents to ensure a reliable diagnosis of recurrent ischemic stroke. The early stroke progression was described as an incremental increase in the NIHSS score by &#x02265;2 points in the total score or &#x02265;1 point in motor power within 1 week after admission (excluding hemorrhage transformation of cerebral infarction and symptomatic intracranial hemorrhage), accompanied by the new ischemic signals on brain MRI or computed tomography (CT) (<xref ref-type="bibr" rid="B12">12</xref>). Early recurrent ischemic stroke (ERIS) was defined as the occurrence of an ischemic stroke in other independent arterial regions confirmed by clinical symptoms or by CT/MRI imaging techniques (<xref ref-type="bibr" rid="B13">13</xref>). Hemorrhagic transformation was defined as the hemorrhage in the infarct area or the corresponding vascular distribution area after acute cerebral infarction (<xref ref-type="bibr" rid="B14">14</xref>). Complications during hospitalization were defined as at least one syndrome, namely, urinary infection, pulmonary infection, gastrointestinal bleeding, deep vein thrombosis, other organ dysfunction, and/or acute coronary syndromes within 7 days. Patients or their authorized proxies were interviewed at 3 months by telephone by trained research coordinators. Two trained researchers in Beijing Tian Tan hospital completed all the telephone follow-ups of patients. Trained stroke neurologists assessed the NIHSS. The mRS at the 3-month time point was evaluated by trained and experienced neurologists by a telephone assessment using a standardized structured questionnaire. An experienced neurologist independently confirmed all the followed-up assessments. They were also blinded to imaging information of all patients.</p>
</sec>
<sec>
<title>Statistical Analysis</title>
<p>Continuous variables were described by means [standard deviations (SDs)] or medians [interquartile ranges (IQRs)], and categorical data were expressed as frequency and percentage. To analyze the difference between the IPH group and the non-IPH group, Student&#x00027;s <italic>t</italic>-test or Mann&#x02013;Whitney <italic>U</italic>-test were used for continuous variables according to a normal distribution, and chi-squared test or Fisher exact test for categorical variables. Univariate and multivariable Cox regression analyses were conducted to study predictors of poor prognosis of stroke by calculating odds ratio (OR) and 95% confidence interval. Statistical analyses were performed using SPSS version 22.0 (IBM, NY, USA). A two-sided <italic>p</italic> &#x0003C; 0.05 was considered statistically significant.</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<title>Results</title>
<p>One hundred seventy-one patients were enrolled from January 2011 to December 2013, and 15 patients were excluded for the following reasons: (1) 10 patients were lost; and (2) the image quality of 5 patients was poor. Thus, a total of 156 patients were included in the final statistical analysis, including 108 males (69.2%) with a mean age of (61.18 &#x000B1; 10.12, 33&#x02013;85) years. The median day of follow-up time was [IQR, 93 (78&#x02013;110)]. Thirty-two patients (20.5%) had a 3-month poor prognosis (<xref ref-type="fig" rid="F1">Figure 1</xref>).</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption><p>Flow chart of study patients.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fneur-12-780436-g0001.tif"/>
</fig>
<p>Intraplaque hemorrhage detected by HR VWMRI was found in 30 (20.5%) patients (<xref ref-type="fig" rid="F2">Figure 2</xref>). There were significant differences in the age (mean, 66.30 &#x000B1; 8.27 vs. 59.96 &#x000B1; 10.16, <italic>p</italic> = 0.002), gender (male, 86.7 vs. 65.1%, <italic>p</italic> = 0.021), smoking history (60.0 vs. 31.7%, <italic>p</italic> = 0.004), NIHSS on admission [IQR, 3 (0&#x02013;8) vs. 4 (2&#x02013;12), <italic>p</italic> = 0.031], and DBP on admission (mean, 81.52 &#x000B1; 11.40 vs. 86.94 &#x000B1; 12.12 mmHg, <italic>p</italic> = 0.037) between the IPH group and the non-IPH group (<xref ref-type="table" rid="T1">Table 1</xref>).</p>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption><p>Distribution of modified Rankin scale (mRS) scores at 3 months in patients with acute ischemic stroke.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fneur-12-780436-g0002.tif"/>
</fig>
<table-wrap position="float" id="T1">
<label>Table 1</label>
<caption><p>Demographic and clinical characteristics in patients.</p></caption>
<table frame="hsides" rules="groups">
<thead><tr>
<th valign="top" align="left"><bold>Variables</bold></th>
<th valign="top" align="center"><bold>Total (<italic>n</italic> &#x0003D; 156)</bold></th>
<th valign="top" align="center"><bold>IPH group (<italic>n</italic> &#x0003D; 30)</bold></th>
<th valign="top" align="center"><bold>Non-IPH group (<italic>n</italic> &#x0003D; 126)</bold></th>
<th valign="top" align="center"><bold><italic>P-</italic>value</bold></th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">Gender, male, <italic>n</italic> (%)</td>
<td valign="top" align="center">108 (69.2)</td>
<td valign="top" align="center">26 (86.7)</td>
<td valign="top" align="center">82 (65.1)</td>
<td valign="top" align="center"><bold>0.021</bold></td>
</tr>
<tr>
<td valign="top" align="left">Age, years</td>
<td valign="top" align="center">61.18 &#x000B1; 10.12</td>
<td valign="top" align="center">66.30 &#x000B1; 8.27</td>
<td valign="top" align="center">59.96 &#x000B1; 10.16</td>
<td valign="top" align="center"><bold>0.002</bold></td>
</tr>
<tr>
<td valign="top" align="left">Hypertension, <italic>n</italic> (%)</td>
<td valign="top" align="center">107 (68.6)</td>
<td valign="top" align="center">22 (73.7)</td>
<td valign="top" align="center">85 (67.5)</td>
<td valign="top" align="center">0.533</td>
</tr>
<tr>
<td valign="top" align="left">Diabetes mellitus, <italic>n</italic> (%)</td>
<td valign="top" align="center">50 (32.1)</td>
<td valign="top" align="center">13 (43.3)</td>
<td valign="top" align="center">37 (29.4)</td>
<td valign="top" align="center">0.141</td>
</tr>
<tr>
<td valign="top" align="left">Coronary heart disease, <italic>n</italic> (%)</td>
<td valign="top" align="center">18 (11.5)</td>
<td valign="top" align="center">2 (6.7)</td>
<td valign="top" align="center">16 (12.7)</td>
<td valign="top" align="center">0.528</td>
</tr>
<tr>
<td valign="top" align="left">Hyperlipidemia, <italic>n</italic> (%)</td>
<td valign="top" align="center">59 (37.8)</td>
<td valign="top" align="center">7 (23.3)</td>
<td valign="top" align="center">59 (37.8)</td>
<td valign="top" align="center">0.069</td>
</tr>
<tr>
<td valign="top" align="left">Prior stroke/TIA, <italic>n</italic> (%)</td>
<td valign="top" align="center">31 (19.9)</td>
<td valign="top" align="center">4 (13.3)</td>
<td valign="top" align="center">27 (21.4)</td>
<td valign="top" align="center">0.318</td>
</tr>
<tr>
<td valign="top" align="left">Smoking history, <italic>n</italic> (%)</td>
<td valign="top" align="center">58 (37.2)</td>
<td valign="top" align="center">18 (60.0)</td>
<td valign="top" align="center">40 (31.7)</td>
<td valign="top" align="center"><bold>0.004</bold></td>
</tr>
<tr>
<td valign="top" align="left">Alcohol consuming, <italic>n</italic> (%)</td>
<td valign="top" align="center">51 (32.7)</td>
<td valign="top" align="center">9 (30.0)</td>
<td valign="top" align="center">42 (33.3)</td>
<td valign="top" align="center">0.726</td>
</tr>
<tr>
<td valign="top" align="left">Family history of stroke, <italic>n</italic> (%)</td>
<td valign="top" align="center">21 (13.5)</td>
<td valign="top" align="center">2 (6.7)</td>
<td valign="top" align="center">19 (15.1)</td>
<td valign="top" align="center">0.371</td>
</tr>
<tr>
<td valign="top" align="left">SBP on admission, mmHg</td>
<td valign="top" align="center">144.60 &#x000B1; 21.75</td>
<td valign="top" align="center">143.15 &#x000B1; 21.01</td>
<td valign="top" align="center">144.93 &#x000B1; 21.99</td>
<td valign="top" align="center">0.702</td>
</tr>
<tr>
<td valign="top" align="left">DBP on admission, mmHg</td>
<td valign="top" align="center">85.92 &#x000B1; 12.18</td>
<td valign="top" align="center">81.52 &#x000B1; 11.40</td>
<td valign="top" align="center">86.94 &#x000B1; 12.12</td>
<td valign="top" align="center"><bold>0.037</bold></td>
</tr>
<tr>
<td valign="top" align="left">NIHSS on admission, IQR</td>
<td valign="top" align="center">4 (0&#x02013;12)</td>
<td valign="top" align="center">3 (0&#x02013;8)</td>
<td valign="top" align="center">4 (2&#x02013;12)</td>
<td valign="top" align="center"><bold>0.031</bold></td>
</tr>
<tr>
<td valign="top" align="left">Pre-admission mRS, IQR</td>
<td valign="top" align="center">1 (0&#x02013;2)</td>
<td valign="top" align="center">1 (0&#x02013;2)</td>
<td valign="top" align="center">1 (0&#x02013;2)</td>
<td valign="top" align="center">0.059</td>
</tr>
<tr>
<td valign="top" align="left">hs-CRP, IQR, mg/L</td>
<td valign="top" align="center">2.60 (0.00&#x02013;45.90)</td>
<td valign="top" align="center">3.30 (0.00&#x02013;17.90)</td>
<td valign="top" align="center">2.50 (0.00&#x02013;45.90)</td>
<td valign="top" align="center">0.617</td>
</tr>
<tr>
<td valign="top" align="left">TC, mmol/L</td>
<td valign="top" align="center">4.34 &#x000B1; 1.07</td>
<td valign="top" align="center">4.25 &#x000B1; 1.13</td>
<td valign="top" align="center">4.36 &#x000B1; 1.06</td>
<td valign="top" align="center">0.634</td>
</tr>
<tr>
<td valign="top" align="left">TG, IQR, mmol/L</td>
<td valign="top" align="center">1.36 (0.50&#x02013;8.44)</td>
<td valign="top" align="center">1.29 (0.67&#x02013;3.89)</td>
<td valign="top" align="center">1.37 (0.50&#x02013;8.44)</td>
<td valign="top" align="center">0.507</td>
</tr>
<tr>
<td valign="top" align="left">LDL-C, mmol/L</td>
<td valign="top" align="center">2.61 &#x000B1; 0.96</td>
<td valign="top" align="center">2.39 &#x000B1; 0.91</td>
<td valign="top" align="center">2.66 &#x000B1; 0.96</td>
<td valign="top" align="center">0.184</td>
</tr>
<tr>
<td valign="top" align="left">HDL-C, mmol/L</td>
<td valign="top" align="center">1.07 &#x000B1; 0.34</td>
<td valign="top" align="center">1.19 &#x000B1; 0.56</td>
<td valign="top" align="center">1.05 &#x000B1; 0.27</td>
<td valign="top" align="center">0.209</td>
</tr>
<tr>
<td valign="top" align="left">Hcy, IQR, umol/L</td>
<td valign="top" align="center">17.10 (6.60&#x02013;75.00)</td>
<td valign="top" align="center">21.17 (10.50&#x02013;51.20)</td>
<td valign="top" align="center">16.70 (6.60&#x02013;75.00)</td>
<td valign="top" align="center">0.201</td>
</tr>
<tr>
<td valign="top" align="left">Stenosis rate of CA, %</td>
<td valign="top" align="center">62.77 &#x000B1; 12.08</td>
<td valign="top" align="center">65.26 &#x000B1; 14.32</td>
<td valign="top" align="center">62.18 &#x000B1; 11.47</td>
<td valign="top" align="center">0.279</td>
</tr>
<tr>
<td valign="top" align="left">Stenotic degree of CA</td>
<td/>
<td/>
<td/>
<td valign="top" align="center"><bold>0.090</bold></td>
</tr>
<tr>
<td valign="top" align="left">Mild stenosis (&#x0003C;50%), <italic>n</italic> (%)</td>
<td valign="top" align="center">20 (12.8)</td>
<td valign="top" align="center">4 (13.3)</td>
<td valign="top" align="center">16 (12.7)</td>
<td valign="top" align="center">&#x02014;</td>
</tr>
<tr>
<td valign="top" align="left">Moderate stenosis (50&#x02013;69%), <italic>n</italic> (%)</td>
<td valign="top" align="center">92 (59.0)</td>
<td valign="top" align="center">13 (43.3)</td>
<td valign="top" align="center">79 (62.7)</td>
<td valign="top" align="center">&#x02014;</td>
</tr>
<tr>
<td valign="top" align="left">Severe stenosis/occlusion (&#x0003E;70%), <italic>n</italic> (%)</td>
<td valign="top" align="center">44(28.2)</td>
<td valign="top" align="center">13 (43.3)</td>
<td valign="top" align="center">31 (24.6)</td>
<td valign="top" align="center">&#x02014;</td>
</tr>
<tr>
<td valign="top" align="left">LA, mm<sup>2</sup></td>
<td valign="top" align="center">16.86 &#x000B1; 6.99</td>
<td valign="top" align="center">14.73 &#x000B1; 7.94</td>
<td valign="top" align="center">17.37 &#x000B1; 6.67</td>
<td valign="top" align="center"><bold>0.063</bold></td>
</tr>
<tr>
<td valign="top" align="left">WA, IQR, mm<sup>2</sup></td>
<td valign="top" align="center">30.65 (19.11&#x02013;114.10)</td>
<td valign="top" align="center">34.56 (21.68&#x02013;114.10)</td>
<td valign="top" align="center">29.61(19.11&#x02013;54.03)</td>
<td valign="top" align="center"><bold>&#x0003C;0.001</bold></td>
</tr>
<tr>
<td valign="top" align="left">VA, IQR, mm<sup>2</sup></td>
<td valign="top" align="center">74.45 (43.00&#x02013;162.11)</td>
<td valign="top" align="center">73.22 (43.00&#x02013;162.11)</td>
<td valign="top" align="center">74.45(45.01&#x02013;133.74)</td>
<td valign="top" align="center">0.269</td>
</tr>
<tr>
<td valign="top" align="left">NWI, IQR</td>
<td valign="top" align="center">0.42 (0.28&#x02013;0.69)</td>
<td valign="top" align="center">0.46 (0.40&#x02013;0.69)</td>
<td valign="top" align="center">0.41(0.28&#x02013;0.63)</td>
<td valign="top" align="center"><bold>&#x0003C;0.001</bold></td>
</tr>
<tr>
<td valign="top" align="left">WT, IQR, mm</td>
<td valign="top" align="center">1.11 (0.81&#x02013;3.14)</td>
<td valign="top" align="center">1.33 (1.06&#x02013;3.14)</td>
<td valign="top" align="center">1.07(0.81&#x02013;1.80)</td>
<td valign="top" align="center"><bold>&#x0003C;0.001</bold></td>
</tr>
<tr>
<td valign="top" align="left">PA, IQR, mm<sup>2</sup></td>
<td valign="top" align="center">24.42 (8.60&#x02013;74.29)</td>
<td valign="top" align="center">38.32 (11.42&#x02013;71.35)</td>
<td valign="top" align="center">22.22 (8.60&#x02013;74.29)</td>
<td valign="top" align="center"><bold>&#x0003C;0.001</bold></td>
</tr>
<tr>
<td valign="top" align="left">RI</td>
<td valign="top" align="center">0.75 &#x000B1; 0.08</td>
<td valign="top" align="center">0.68 &#x000B1; 0.07</td>
<td valign="top" align="center">0.76 &#x000B1; 0.07</td>
<td valign="top" align="center"><bold>&#x0003C;0.001</bold></td>
</tr>
<tr>
<td valign="top" align="left">Calcification, <italic>n</italic> (%)</td>
<td valign="top" align="center">85 (54.5)</td>
<td valign="top" align="center">26 (86.7)</td>
<td valign="top" align="center">59 (46.8)</td>
<td valign="top" align="center"><bold>&#x0003C;0.001</bold></td>
</tr>
<tr>
<td valign="top" align="left">Loose matrix, <italic>n</italic> (%)</td>
<td valign="top" align="center">74 (47.4)</td>
<td valign="top" align="center">24 (80.0)</td>
<td valign="top" align="center">50 (39.7)</td>
<td valign="top" align="center"><bold>&#x0003C;0.001</bold></td>
</tr>
<tr>
<td valign="top" align="left">LRNC, <italic>n</italic> (%)</td>
<td valign="top" align="center">127 (81.4)</td>
<td valign="top" align="center">30 (100.0)</td>
<td valign="top" align="center">97 (77.7)</td>
<td valign="top" align="center"><bold>0.004</bold></td>
</tr>
<tr>
<td valign="top" align="left">FCR, <italic>n</italic> (%)</td>
<td valign="top" align="center">4 (2.6)</td>
<td valign="top" align="center">4 (13.3)</td>
<td valign="top" align="center">0 (0.0)</td>
<td valign="top" align="center"><bold>0.001</bold></td>
</tr>
<tr>
<td valign="top" align="left">Median on admission-to-following time, d (IQR)</td>
<td valign="top" align="center">93 (78&#x02013;110)</td>
<td valign="top" align="center">93 (83&#x02013;99)</td>
<td valign="top" align="center">93 (78&#x02013;110)</td>
<td valign="top" align="center">0.750</td>
</tr>
<tr>
<td valign="top" align="left">mRS at 3 months, IQR</td>
<td valign="top" align="center">2 (0&#x02013;5)</td>
<td valign="top" align="center">3 (0&#x02013;5)</td>
<td valign="top" align="center">2 (0&#x02013;5)</td>
<td valign="top" align="center">0.870</td>
</tr>
<tr>
<td valign="top" align="left" colspan="5">Medication at 3 months</td>
</tr>
<tr>
<td valign="top" align="left">Aspirin, <italic>n</italic> (%)</td>
<td valign="top" align="center">89 (57.1)</td>
<td valign="top" align="center">19 (63.3)</td>
<td valign="top" align="center">70 (55.6)</td>
<td valign="top" align="center">0.439</td>
</tr>
<tr>
<td valign="top" align="left">Clopidogrel, <italic>n</italic> (%)</td>
<td valign="top" align="center">18 (11.5)</td>
<td valign="top" align="center">1 (3.3)</td>
<td valign="top" align="center">17 (13.5)</td>
<td valign="top" align="center">0.200</td>
</tr>
<tr>
<td valign="top" align="left">Statins, <italic>n</italic> (%)</td>
<td valign="top" align="center">68 (43.6)</td>
<td valign="top" align="center">8 (26.7)</td>
<td valign="top" align="center">60 (47.6)</td>
<td valign="top" align="center">0.038</td>
</tr>
<tr>
<td valign="top" align="left">Antihypertension, <italic>n</italic> (%)</td>
<td valign="top" align="center">49 (31.4)</td>
<td valign="top" align="center">9 (30.0)</td>
<td valign="top" align="center">40 (31.7)</td>
<td valign="top" align="center">0.853</td>
</tr>
<tr>
<td valign="top" align="left">Hypoglycemic, <italic>n</italic> (%)</td>
<td valign="top" align="center">47 (30.1)</td>
<td valign="top" align="center">11 (36.7)</td>
<td valign="top" align="center">36 (28.6)</td>
<td valign="top" align="center">0.385</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>IPH, intraplaque hemorrhage; TIA, transient ischemic attack; SBP, systolic blood pressure; DBP, diastolic blood pressure; hs-CRP, hypersensitive c-reactive protein; TC, cholesterol; TG, triglycerides; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; Hcy, homocysteine; CA, carotid artery; LA, lumen area; WA, wall area; VA, vessel area; NWI, normalized wall index; WT, wall thickness; PA, plaque area; RI, remodeling index; LRNC, lipo-rich necrotic core; FCR, fibrous cap rupture; NIHSS, national institutes of health stroke scale; mRS, modified Rankin scale; IQR, interquartile range</italic>.</p>
</table-wrap-foot>
</table-wrap>
<p>Between the IPH group and the non-IPH group, there was no significant difference in the degree of stenosis (<italic>p</italic> = 0.279), lumen area (LA) (<italic>p</italic> = 0.063), and vessel area (VA) (<italic>p</italic> = 0.269). However, there were significant differences in the wall area (WA) [IQR, 34.56 (21.68&#x02013;114.10) mm<sup>2</sup> vs. 29.61 (19.11&#x02013;54.03) mm<sup>2</sup>, <italic>p</italic> &#x0003C; 0.001], normalized wall index (NMI) [IQR, 0.46 (0.40&#x02013;0.69) vs. 41 (0.28&#x02013;0.63), <italic>p</italic> &#x0003C; 0.001], wall thickness (WI) [IQR, 1.33 (1.06&#x02013;3.14) mm vs. 1.07 (0.81&#x02013;1.80) mm, <italic>p</italic> &#x0003C; 0.001], plaque area (PA) [IQR, 38.32 (11.42&#x02013;71.35) mm<sup>2</sup> vs. 22.22 (8.60&#x02013;74.29) mm<sup>2</sup>, <italic>p</italic> &#x0003C; 0.001], and remodeling index (RI) (mean, 0.68 &#x000B1; 0.07 vs. 76 &#x000B1; 0.07, <italic>p</italic> &#x0003C; 0.001) (<xref ref-type="table" rid="T1">Table 1</xref>).</p>
<p>During the follow-up, 32 patients (20.5%) had a poor functional outcome. The proportion of poor function outcome is 36.7% for the IPH group and 16.7% for the non-IPH group (crude OR 2.32; 95%CI 1.12&#x02013;4.81; <italic>p</italic> = 0.024) (<xref ref-type="fig" rid="F3">Figure 3</xref>). After adjusting the baseline variables as age, gender, smoking history, NIHSS on admission, DBP on admission, stenosis rate of CA, calcification, loose matrix, LRNC, and statins accepted at 3 months, there was still a statistical difference (adjusted OR 3.66; 95%CI 1.68&#x02013;7.94; <italic>p</italic> = 0.001) between the two groups (<xref ref-type="table" rid="T2">Table 2</xref>). Regarding the second outcomes, the proportion of early stroke progression, early recurrent ischemic stroke, and hemorrhagic transformation in the IPH group was significantly higher (all <italic>p</italic> &#x0003C; 0.05, <xref ref-type="table" rid="T2">Table 2</xref>).</p>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption><p>A 61-year-old male patient presented with right ischemic stroke. The plaque is shown at the beginning of the right internal carotid artery on <bold>(a)</bold> 3D MERGE, <bold>(b)</bold> TOF, and <bold>(c)</bold> T1W (white arrow). The intraplaque hemorrhage (IPH) is characterized by hyperintensities on <bold>(d)</bold> T2WI and <bold>(e)</bold> MPRAGE (yellow arrow). 3D MERG, 3D multiple-echo recalled gradient-echo; 3D-TOF, three-dimensional time of flight; T1W, T1-weighted; T2W, T2-weighted; MPRAGE, magnetization-prepared rapid acquisition gradient-echo.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fneur-12-780436-g0003.tif"/>
</fig>
<table-wrap position="float" id="T2">
<label>Table 2</label>
<caption><p> Outcomes at 3 months after stroke onset in carotid plaque hemorrhage (IPH) group vs. non-IPH group.</p></caption>
<table frame="hsides" rules="groups">
<thead><tr>
<th valign="top" align="left"><bold>Outcome</bold></th>
<th valign="top" align="center" colspan="2" style="border-bottom: thin solid #000000;"><bold>No. (%) of patients</bold></th>
<th valign="top" align="center"><bold>Unadjusted OR (95% CI)</bold></th>
<th valign="top" align="center"><bold><italic>P</italic>-value</bold></th>
<th valign="top" align="center"><bold>Adjusted OR (95% CI)<xref ref-type="table-fn" rid="TN1"><sup>&#x0002A;</sup></xref></bold></th>
<th valign="top" align="center"><bold><italic>P</italic>-value</bold></th>
</tr>
<tr>
<th/>
<th valign="top" align="center"><bold>IPH group (<italic>n</italic> &#x0003D; 30)</bold></th>
<th valign="top" align="center"><bold>Non-IPH group (<italic>n</italic> &#x0003D; 126)</bold></th>
<th/>
<th/>
<th/>
<th/>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left" colspan="7">Primary outcome</td>
</tr>
<tr>
<td valign="top" align="left">mRS 3&#x02013;6 at 3 months</td>
<td valign="top" align="center">11 (36.7)</td>
<td valign="top" align="center">21 (16.7)</td>
<td valign="top" align="center">2.32 (1.12&#x02013;4.81)</td>
<td valign="top" align="center">0.024</td>
<td valign="top" align="center">3.66 (1.68&#x02013;7.94)</td>
<td valign="top" align="center"><bold>0.001</bold></td>
</tr>
<tr>
<td valign="top" align="left" colspan="7">Second outcomes</td>
</tr>
<tr>
<td valign="top" align="left">Early stroke progression</td>
<td valign="top" align="center">5 (16.7)</td>
<td valign="top" align="center">4 (3.2)</td>
<td valign="top" align="center">5.25 (1.41&#x02013;19.60)</td>
<td valign="top" align="center">0.014</td>
<td valign="top" align="center">5.43 (1.45&#x02013;20.25)</td>
<td valign="top" align="center"><bold>0.012</bold></td>
</tr>
<tr>
<td valign="top" align="left">Early recurrent ischemic stroke</td>
<td valign="top" align="center">15 (50.0)</td>
<td valign="top" align="center">14 (11.1)</td>
<td valign="top" align="center">4.90 (2.37&#x02013;10.17)</td>
<td valign="top" align="center">0.000</td>
<td valign="top" align="center">7.49 (3.13&#x02013;17.94)</td>
<td valign="top" align="center"><bold>&#x0003C;0.001</bold></td>
</tr>
<tr>
<td valign="top" align="left">Hemorrhagic transformation</td>
<td valign="top" align="center">1 (3.3)</td>
<td valign="top" align="center">3 (2.4)</td>
<td valign="top" align="center">1.51 (0.16&#x02013;14.53)</td>
<td valign="top" align="center">0.722</td>
<td valign="top" align="center">-</td>
<td valign="top" align="center"><bold>0.010</bold></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="TN1">
<label>&#x0002A;</label>
<p><italic>Adjusted baseline variables: age, gender, smoking history, NIHSS on admission, DBP on admission, stenosis rate of CA, calcification, loose matrix, LRNC, and statins at 3 months</italic>.</p></fn>
<p><italic>mRS, modified Rankin Scale; IPH, intraplaque hemorrhage; CA, carotid artery; LRNC, lipo-rich necrotic core. OR, odds ratio; CI, confidence interval; mRS, modified Rankin Scale; IPH, intraplaque hemorrhage; CA, carotid artery; LRNC, lipo-rich necrotic core</italic>.</p>
</table-wrap-foot>
</table-wrap>
</sec>
<sec sec-type="discussion" id="s4">
<title>Discussion</title>
<p>Our study investigated the association between IPH detected by HR VWMRI and functional outcome at 3 months after stroke onset. Our study found that the incidence of carotid plaque IPH in patients with acute ischemic stroke was 19.27%. Meanwhile, the percentage of IPH was significantly higher than other plaque vulnerable features, which could reach 61.54%.</p>
<p>Our previous study has confirmed that IPH was associated with ipsilateral ischemic stroke recurrence, especially in the first 3 months after acute ischemic stroke. So, we hypothesized that IPH might be related to a 3-month poor prognosis. In our study, we found the proportion of patients with poor functional outcome in the IPH group is much higher than patients in the non-IPH group, which could be 3.66 times higher even after adjusting for confounding factors (including age, gender, smoking history, NIHSS on admission, DBP on admission, stenosis rate of CA, calcification, loose matrix, LRNC, and statins accepted at 3 months). However, we still wanted to know why the patients with IPH might be more prone to have a poor prognosis. So, we defined the early stroke progression, early recurrent ischemic stroke, and hemorrhagic transformation as the second outcomes. Our study found that patients with IPH might be more likely to occur early stroke progression, recurrent ischemic stroke, and hemorrhagic transformation.</p>
<p>Several studies have confirmed that IPH is associated with plaque progression (<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B16">16</xref>). Takaya et al. (<xref ref-type="bibr" rid="B17">17</xref>) followed the asymptomatic patients with carotid artery stenosis rate of 50&#x02013;70% for 18 months. They found that the volume of the carotid artery wall and the percentage of lipid-rich necrotic core volume in the patients with IPH detected by MRI at baseline were significantly higher than in the control group. Meanwhile, the patients with IPH at baseline were also more likely to have new IPH at 18 months (43 vs. 0%; <italic>p</italic> = 0.006). According to the pathophysiological mechanism of plaque progression, some scholars believed that the hemoglobin would be released extracellularly after red blood cells are phagocytosed by macrophage. The free hemoglobin would increase inflammation, lipid core expansion, and oxidative stress, leading to plaque progression. IPH also carried proteolytic enzyme, leading to the degradation and destruction of the fibrous cap, and, finally, to the plaque rupture (<xref ref-type="bibr" rid="B18">18</xref>&#x02013;<xref ref-type="bibr" rid="B20">20</xref>). Due to the limitations of this study, we did not study the pathophysiological process of IPH leading to the secondary outcomes, though it might be the research direction and hot spot in the future.</p>
<p>Our study still has some shortcomings. Firstly, because it is a single-center study with small sample size, the statistical results might be biased. Secondly, we did not make further study on the dynamic evolution of IPH, so we still do not know the pathophysiological mechanism of PH leading to poor functional outcome. Thirdly, our study did not exclude other risk factors affecting the prognosis of stroke, such as intracranial vascular artery disease, collateral circulation, and cerebral blood flow reserve capacity, which may be some errors in the results. Fourthly, we did not register the TOAST subtypes in our study, and it is a pity of the study. However, we have tried our best to rule out cardiogenic sources. We also hope to see the results of a large sample and more rigorous research in the future.</p>
</sec>
<sec sec-type="conclusions" id="s5">
<title>Conclusion</title>
<p>Compared with patients without IPH, patients with IPH have a higher risk of poor 3-month outcome after stroke onset. Based on this, we should not overlook the potential risk of IPH. It might be essential to understand the underlying pathophysiological mechanism of plaque vulnerability and the molecular biomarkers combined with neuroimaging markers.</p>
</sec>
<sec sec-type="data-availability" id="s6">
<title>Data Availability Statement</title>
<p>The original contributions presented in the study are included in the article/<xref ref-type="supplementary-material" rid="SM1">Supplementary Material</xref>, further inquiries can be directed to the corresponding author/s.</p>
</sec>
<sec id="s7">
<title>Ethics Statement</title>
<p>The studies involving human participants were reviewed and approved by the Ethics Committee of Beijing Tiantan Hospital. Written informed consent to participate in this study was provided by the patient/participants or patient/participants&#x00027; legal guardian/next of kin.</p>
</sec>
<sec id="s8">
<title>Author Contributions</title>
<p>FC, XZ, XGo, BS, and YJ: concept and design. FC, YL, and XGe: drafting of the manuscript. XB and JJ: critical revision of the manuscript for important intellectual content. YL, BS, and YJ: provision of study material or patients. FC, YL, JJ, AW, XB, BS, YJ, and XGo: collection and assembly of data. XZ and BS: check and approve of clinical definition and supervision. FC and AW: data analysis. FC, AW, XB, BS, JJ, and XGe: data interpretation. XZ, BS, and YJ: administrative, and technical or material support. All authors: final approval of manuscript.</p>
</sec>
<sec sec-type="funding-information" id="s9">
<title>Funding</title>
<p>The study was supported by grants from the Beijing Natural Science Foundation (Z200016).</p>
</sec>
<sec sec-type="COI-statement" id="conf1">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s10">
<title>Publisher&#x00027;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec> </body>
<back>
<ack><p>Thanks were due to Professor Xihai Zhao from Tsinghua University for his selfless assistance with the experiment and Dr. Donghua Mi from Beijing Tiantan Hospital for her valuable discussion.</p>
</ack>
<sec sec-type="supplementary-material" id="s11">
<title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fneur.2021.780436/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fneur.2021.780436/full#supplementary-material</ext-link></p>
<supplementary-material xlink:href="Table_1.docx" id="SM1" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Table_2.DOCX" id="SM2" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Table_3.DOCX" id="SM3" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Table_4.DOCX" id="SM4" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Table_5.DOCX" id="SM5" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Table_6.DOCX" id="SM6" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Data_Sheet_1.XLS" id="SM7" mimetype="application/vnd.ms-excel" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>

<ref-list>
<title>References</title>
<ref id="B1">
<label>1.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>L</given-names></name> <name><surname>Wang</surname> <given-names>D</given-names></name> <name><surname>Wong</surname> <given-names>KS</given-names></name> <name><surname>Wang</surname> <given-names>Y</given-names></name></person-group>. <article-title>Stroke and stroke care in China: huge burden, significant workload, and a national priority</article-title>. <source>Stroke.</source> (<year>2011</year>) <volume>42</volume>:<fpage>3651</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1161/STROKEAHA.111.635755</pub-id><pub-id pub-id-type="pmid">22052510</pub-id></citation></ref>
<ref id="B2">
<label>2.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dharmakidari</surname> <given-names>S</given-names></name> <name><surname>Bhattacharya</surname> <given-names>P</given-names></name> <name><surname>Chaturvedi</surname> <given-names>S</given-names></name></person-group>. <article-title>Carotid artery stenosis: medical therapy, surgery, and stenting</article-title>. <source>Curr Neurol Neurosci Rep.</source> (<year>2017</year>) <volume>17</volume>:<fpage>77</fpage>. <pub-id pub-id-type="doi">10.1007/s11910-017-0786-2</pub-id><pub-id pub-id-type="pmid">28825185</pub-id></citation></ref>
<ref id="B3">
<label>3.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Al-Khaled</surname> <given-names>M</given-names></name> <name><surname>Scheef</surname> <given-names>B</given-names></name></person-group>. <article-title>Symptomatic carotid stenosis and stroke risk in patients with transient ischemic attack according to the tissue-based definition</article-title>. <source>Int J Neurosci.</source> (<year>2016</year>) <volume>126</volume>:<fpage>888</fpage>&#x02013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.3109/00207454.2015.1077834</pub-id><pub-id pub-id-type="pmid">26312923</pub-id></citation></ref>
<ref id="B4">
<label>4.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname> <given-names>X</given-names></name> <name><surname>Li</surname> <given-names>R</given-names></name> <name><surname>Hippe</surname> <given-names>DS</given-names></name> <name><surname>Hatsukami</surname> <given-names>TS</given-names></name> <name><surname>Yuan</surname> <given-names>C</given-names></name> <name><surname>Investigators</surname> <given-names>C-I</given-names></name></person-group>. <article-title>Chinese Atherosclerosis Risk Evaluation (CARE II) study: a novel cross-sectional, multicentre study of the prevalence of high-risk atherosclerotic carotid plaque in Chinese patients with ischaemic cerebrovascular events-design and rationale</article-title>. <source>Stroke Vasc Neurol.</source> (<year>2017</year>) <volume>2</volume>:<fpage>15</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1136/svn-2016-000053</pub-id><pub-id pub-id-type="pmid">28959486</pub-id></citation></ref>
<ref id="B5">
<label>5.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname> <given-names>P</given-names></name> <name><surname>Chen</surname> <given-names>Z</given-names></name> <name><surname>Hippe</surname> <given-names>DS</given-names></name> <name><surname>Watase</surname> <given-names>H</given-names></name> <name><surname>Sun</surname> <given-names>B</given-names></name> <name><surname>Lin</surname> <given-names>R</given-names></name> <etal/></person-group>. <article-title>Association between carotid bifurcation geometry and atherosclerotic plaque vulnerability: a Chinese atherosclerosis risk evaluation study</article-title>. <source>Arterioscler Thromb Vasc Biol.</source> (<year>2020</year>) <volume>40</volume>:<fpage>1383</fpage>&#x02013;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1161/ATVBAHA.119.313830</pub-id><pub-id pub-id-type="pmid">32160772</pub-id></citation></ref>
<ref id="B6">
<label>6.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>D</given-names></name> <name><surname>Ji</surname> <given-names>Y</given-names></name> <name><surname>Wang</surname> <given-names>D</given-names></name> <name><surname>Watase</surname> <given-names>H</given-names></name> <name><surname>Hippe</surname> <given-names>DS</given-names></name> <name><surname>Zhao</surname> <given-names>X</given-names></name> <etal/></person-group>. <article-title>Comparison of carotid atherosclerotic plaques between subjects in Northern and Southern China: a Chinese atherosclerosis risk evaluation study</article-title>. <source>Stroke Vasc Neurol.</source> (<year>2020</year>) <volume>5</volume>:<fpage>138</fpage>&#x02013;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1136/svn-2019-000288</pub-id><pub-id pub-id-type="pmid">32404502</pub-id></citation></ref>
<ref id="B7">
<label>7.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Finn</surname> <given-names>AV</given-names></name> <name><surname>Nakano</surname> <given-names>M</given-names></name> <name><surname>Narula</surname> <given-names>J</given-names></name> <name><surname>Kolodgie</surname> <given-names>FD</given-names></name> <name><surname>Virmani</surname> <given-names>R</given-names></name></person-group>. <article-title>Concept of vulnerable/unstable plaque</article-title>. <source>Arterioscler Thromb Vasc Biol.</source> (<year>2010</year>) <volume>30</volume>:<fpage>1282</fpage>&#x02013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1161/ATVBAHA.108.179739</pub-id><pub-id pub-id-type="pmid">20554950</pub-id></citation></ref>
<ref id="B8">
<label>8.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Naghavi</surname> <given-names>M</given-names></name> <name><surname>Libby</surname> <given-names>P</given-names></name> <name><surname>Falk</surname> <given-names>E</given-names></name> <name><surname>Casscells</surname> <given-names>SW</given-names></name> <name><surname>Litovsky</surname> <given-names>S</given-names></name> <name><surname>Rumberger</surname> <given-names>J</given-names></name> <etal/></person-group>. <article-title>From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I</article-title>. <source>Circulation.</source> (<year>2003</year>) <volume>108</volume>:<fpage>1664</fpage>&#x02013;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1161/01.CIR.0000087480.94275.97</pub-id><pub-id pub-id-type="pmid">14557340</pub-id></citation></ref>
<ref id="B9">
<label>9.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Naghavi</surname> <given-names>M</given-names></name> <name><surname>Libby</surname> <given-names>P</given-names></name> <name><surname>Falk</surname> <given-names>E</given-names></name> <name><surname>Casscells</surname> <given-names>SW</given-names></name> <name><surname>Litovsky</surname> <given-names>S</given-names></name> <name><surname>Rumberger</surname> <given-names>J</given-names></name> <etal/></person-group>. <article-title>From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II</article-title>. <source>Circulation.</source> (<year>2003</year>) <volume>108</volume>:<fpage>1772</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1161/01.CIR.0000087481.55887.C9</pub-id><pub-id pub-id-type="pmid">14557340</pub-id></citation></ref>
<ref id="B10">
<label>10.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saam</surname> <given-names>T</given-names></name> <name><surname>Underhill</surname> <given-names>HR</given-names></name> <name><surname>Chu</surname> <given-names>B</given-names></name> <name><surname>Takaya</surname> <given-names>N</given-names></name> <name><surname>Cai</surname> <given-names>J</given-names></name> <name><surname>Polissar</surname> <given-names>NL</given-names></name> <etal/></person-group>. <article-title>Prevalence of American Heart Association type VI carotid atherosclerotic lesions identified by magnetic resonance imaging for different levels of stenosis as measured by duplex ultrasound</article-title>. <source>J Am Coll Cardiol.</source> (<year>2008</year>) <volume>51</volume>:<fpage>1014</fpage>&#x02013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2007.10.054</pub-id><pub-id pub-id-type="pmid">18325441</pub-id></citation></ref>
<ref id="B11">
<label>11.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kwee</surname> <given-names>RM</given-names></name> <name><surname>van Oostenbrugge</surname> <given-names>RJ</given-names></name> <name><surname>Mess</surname> <given-names>WH</given-names></name> <name><surname>Prins</surname> <given-names>MH</given-names></name> <name><surname>van der Geest</surname> <given-names>RJ</given-names></name> <name><surname>ter Berg</surname> <given-names>JWM</given-names></name> <etal/></person-group>. <article-title>MRI of carotid atherosclerosis to identify TIA and stroke patients who are at risk of a recurrence</article-title>. <source>J Magn Reson Imaging.</source> (<year>2013</year>) <volume>37</volume>:<fpage>1189</fpage>&#x02013;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1002/jmri.23918</pub-id><pub-id pub-id-type="pmid">23166040</pub-id></citation></ref>
<ref id="B12">
<label>12.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Seners</surname> <given-names>P</given-names></name> <name><surname>Baron</surname> <given-names>JC</given-names></name></person-group>. <article-title>Revisiting &#x0201C;progressive stroke&#x0201D;: incidence, predictors, pathophysiology, and management of unexplained early neurological deterioration following acute ischemic stroke</article-title>. <source>J Neurol.</source> (<year>2018</year>) <volume>265</volume>:<fpage>216</fpage>&#x02013;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1007/s00415-017-8490-3</pub-id><pub-id pub-id-type="pmid">28455666</pub-id></citation></ref>
<ref id="B13">
<label>13.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rothwell</surname> <given-names>PM</given-names></name> <name><surname>Algra</surname> <given-names>A</given-names></name> <name><surname>Chen</surname> <given-names>Z</given-names></name> <name><surname>Diener</surname> <given-names>HC</given-names></name> <name><surname>Norrving</surname> <given-names>B</given-names></name> <name><surname>Mehta</surname> <given-names>Z</given-names></name></person-group>. <article-title>Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials</article-title>. <source>Lancet.</source> (<year>2016</year>) <volume>388</volume>:<fpage>365</fpage>&#x02013;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(16)30468-8</pub-id><pub-id pub-id-type="pmid">27209146</pub-id></citation></ref>
<ref id="B14">
<label>14.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alvarez-Sabin</surname> <given-names>J</given-names></name> <name><surname>Maisterra</surname> <given-names>O</given-names></name> <name><surname>Santamarina</surname> <given-names>E</given-names></name> <name><surname>Kase</surname> <given-names>CS</given-names></name></person-group>. <article-title>Factors influencing haemorrhagic transformation in ischaemic stroke</article-title>. <source>Lancet Neurol.</source> (<year>2013</year>) <volume>12</volume>:<fpage>689</fpage>&#x02013;<lpage>705</lpage>. <pub-id pub-id-type="doi">10.1016/S1474-4422(13)70055-3</pub-id><pub-id pub-id-type="pmid">23726850</pub-id></citation></ref>
<ref id="B15">
<label>15.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname> <given-names>J</given-names></name> <name><surname>Underhill</surname> <given-names>HR</given-names></name> <name><surname>Hippe</surname> <given-names>DS</given-names></name> <name><surname>Xue</surname> <given-names>Y</given-names></name> <name><surname>Yuan</surname> <given-names>C</given-names></name> <name><surname>Hatsukami</surname> <given-names>TS</given-names></name></person-group>. <article-title>Sustained acceleration in carotid atherosclerotic plaque progression with intraplaque hemorrhage: a long-term time course study</article-title>. <source>JACC Cardiovasc Imaging.</source> (<year>2012</year>) <volume>5</volume>:<fpage>798</fpage>&#x02013;<lpage>804</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcmg.2012.03.014</pub-id><pub-id pub-id-type="pmid">22897993</pub-id></citation></ref>
<ref id="B16">
<label>16.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname> <given-names>J</given-names></name> <name><surname>Balu</surname> <given-names>N</given-names></name> <name><surname>Hippe</surname> <given-names>DS</given-names></name> <name><surname>Xue</surname> <given-names>Y</given-names></name> <name><surname>Dong</surname> <given-names>L</given-names></name> <name><surname>Zhao</surname> <given-names>X</given-names></name> <etal/></person-group>. <article-title>Subclinical carotid atherosclerosis: short-term natural history of lipid-rich necrotic core&#x02013;a multicenter study with MR imaging</article-title>. <source>Radiology.</source> (<year>2013</year>) <volume>268</volume>:<fpage>61</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1148/radiol.13121702</pub-id><pub-id pub-id-type="pmid">23513240</pub-id></citation></ref>
<ref id="B17">
<label>17.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Takaya</surname> <given-names>N</given-names></name> <name><surname>Yuan</surname> <given-names>C</given-names></name> <name><surname>Chu</surname> <given-names>B</given-names></name> <name><surname>Saam</surname> <given-names>T</given-names></name> <name><surname>Polissar</surname> <given-names>NL</given-names></name> <name><surname>Jarvik</surname> <given-names>GP</given-names></name> <etal/></person-group>. <article-title>Presence of intraplaque hemorrhage stimulates progression of carotid atherosclerotic plaques: a high-resolution magnetic resonance imaging study</article-title>. <source>Circulation.</source> (<year>2005</year>) <volume>111</volume>:<fpage>2768</fpage>&#x02013;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.104.504167</pub-id><pub-id pub-id-type="pmid">15911695</pub-id></citation></ref>
<ref id="B18">
<label>18.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moreno</surname> <given-names>PR</given-names></name> <name><surname>Purushothaman</surname> <given-names>M</given-names></name> <name><surname>Purushothaman</surname> <given-names>KR</given-names></name></person-group>. <article-title>Plaque neovascularization: defense mechanisms, betrayal, or a war in progress</article-title>. <source>Ann N Y Acad Sci.</source> (<year>2012</year>) <volume>1254</volume>:<fpage>7</fpage>&#x02013;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1111/j.1749-6632.2012.06497.x</pub-id><pub-id pub-id-type="pmid">22548565</pub-id></citation></ref>
<ref id="B19">
<label>19.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Michel</surname> <given-names>JB</given-names></name> <name><surname>Delbosc</surname> <given-names>S</given-names></name> <name><surname>Ho-Tin-No&#x000E9;</surname> <given-names>B</given-names></name> <name><surname>Leseche</surname> <given-names>G</given-names></name> <name><surname>Nicoletti</surname> <given-names>A</given-names></name> <name><surname>Meilhac</surname> <given-names>O</given-names></name> <etal/></person-group>. <article-title>From intraplaque haemorrhages to plaque vulnerability: biological consequences of intraplaque haemorrhages</article-title>. <source>J Cardiovasc Med.</source> (<year>2012</year>) <volume>13</volume>:<fpage>628</fpage>&#x02013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.2459/JCM.0b013e328357face</pub-id><pub-id pub-id-type="pmid">22929566</pub-id></citation></ref>
<ref id="B20">
<label>20.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Teng</surname> <given-names>Z</given-names></name> <name><surname>Sadat</surname> <given-names>U</given-names></name> <name><surname>Brown</surname> <given-names>AJ</given-names></name> <name><surname>Gillard</surname> <given-names>JH</given-names></name></person-group>. <article-title>Plaque hemorrhage in carotid artery disease: pathogenesis, clinical and biomechanical considerations</article-title>. <source>J Biomech.</source> (<year>2014</year>) <volume>47</volume>:<fpage>847</fpage>&#x02013;<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1016/j.jbiomech.2014.01.013</pub-id><pub-id pub-id-type="pmid">24485514</pub-id></citation></ref>
</ref-list> 
</back>
</article>